Viyash Scientific Limited (BOM:512529)
259.85
+8.85 (3.53%)
At close: Jul 27, 2026
Viyash Scientific Revenue
In the fiscal year ending March 31, 2026, Viyash Scientific had annual revenue of 34.20B INR with 13.75% growth. Viyash Scientific had revenue of 9.20B in the quarter ending March 31, 2026, a decrease of -50.46%.
Revenue
34.20B
Revenue Growth
+13.75%
P/S Ratio
3.32
Revenue / Employee
11.79M
Employees
2,900
Market Cap
113.41B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 34.20B | 4.13B | 13.75% |
| Mar 31, 2025 | 30.07B | 16.37B | 119.52% |
| Mar 31, 2024 | 13.70B | -511.78M | -3.60% |
| Mar 31, 2023 | 14.21B | 80.93M | 0.57% |
| Mar 31, 2022 | 14.13B | 512.01M | 3.76% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jubilant Pharmova | 82.80B |
| Granules India | 56.32B |
| AstraZeneca Pharma India | 22.76B |
| Caplin Point Laboratories | 21.87B |
| FDC Limited | 21.71B |
| Sanofi India | 17.74B |
| Rubicon Research | 17.54B |
| Procter & Gamble Health | 14.08B |
Viyash Scientific News
- 4 weeks ago - Viyash Scientific Slides: FY 2026 - Filings
- 2 months ago - Viyash Scientific Transcript: Q4 25/26 - Transcripts
- 2 months ago - Viyash Scientific Slides: Q4 2026 - Filings
- 2 months ago - Viyash Scientific Quarterly report: Q4 2026 - Filings
- 2 months ago - Viyash Scientific Annual report: Q4 2026 - Filings
- 6 months ago - Viyash Scientific Transcript: Q3 25/26 - Transcripts
- 6 months ago - Viyash Scientific Quarterly report: Q3 2026 - Filings
- 6 months ago - Viyash Scientific Slides: Q3 2026 - Filings